- The number of people experiencing kidney stones is growing worldwide.
- This number is expected to grow due to an increase in diseases that can raise a person’s kidney stone risk, such as obesity or type 2 diabetes.
- Researchers have found that SGLT2 inhibitors — which are used to treat type 2 diabetes — may help lower a person’s risk of developing kidney stones.
As of 2019, there were more than 115 million cases of kidney stones around the world.
Medically known as nephrolithiasis, kidney stones are mineral deposits that form in the kidneys that are too large to easily pass through the urinary tract.
Previous research shows the
Now, researchers from Brigham and Women’s Hospital and Massachusetts General Hospital have found that a type of medication called sodium-glucose contratransporter 2 (SGLT2) inhibitors used to treat type 2 diabetes may help lower a person’s risk of developing kidney stones.
The study was recently published in the journal
SGLT2 inhibitors are a newer class of medications used to help manage blood sugar levels in people with type 2 diabetes.
Taken orally, the medication stops glucose in the blood that is filtered through the kidneys from being reabsorbed by the body. This causes the extra blood sugar to leave the body through urine, lowering blood sugar levels.
Sometimes SGLT2 inhibitors are also prescribed for treating
Past studies have linked SGLT2 inhibitor use to
Dr. Julie Paik, associate professor of medicine in the Division of Pharmacoepidemiology and Pharmacoeconomics and the Division of Renal (Kidney)…
Read the full article here
